MKMandeep Kaur

Mandeep Kaur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mandeep Kaur has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bridging Gaps in Postpartum Depression Research: Pathways to Personalized Medicine in Women’s Mental Health

    by Harshpreet Kaur, Neha Sharma, Joy Das, Mandeep Kaur, Navneet Khurana

    Postpartum depression (PPD) is a prevalent and serious mental health disorder that affects nearly 15% of women after childbirth. It disrupts maternal well-being, infant development, and family relationships, and often remains underdiagnosed due to its complex biological, psychological, and social determinants. Conventional treatment strategies largely follow generalized, symptom-based approaches that fail to address the wide individual variation in hormonal sensitivity, genetic background, and psychosocial context among affected women. This review emphasizes the importance of adopting a personalized medicine framework for the management of PPD. Relevant literature was systematically reviewed from major databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar, focusing on studies published between January 2018 and September 2025. The search covered biological mechanisms, psychosocial influences, and innovative therapeutic approaches integrating pharmacogenomics, hormonal profiling, and culturally sensitive psychotherapies. The analysis highlights that personalized strategies, combining genetic testing for antidepressant response, individualized hormonal modulation, and context-based psychological interventions, offer improved therapeutic precision compared to conventional models. Emerging technologies such as digital health tools and telemedicine further enhance individualized care delivery. Clinically, the integration of personalized medicine transforms PPD management from a uniform, symptom-oriented approach to a patient-centered model that aligns biological and psychosocial dimensions. This paradigm shift has the potential to enhance treatment response, accelerate recovery, and strengthen longterm maternal and child outcomes.

  • Pathogenic Proteins Driving ALS Pathogenesis: Molecular Mechanisms and Translational Therapeutic Perspectives

    by Harshpreet Kaur, Mandeep Kaur, Gopal Krishna Sethi, Arora Sukhpreet Kaur, Aparna Mishra, Neha Sharma

    Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of motor neurons, with protein aggregation as a central pathological hallmark. Key pathogenic proteins, including TDP-43, SOD1, FUS, and dipeptide repeat proteins (DPRs) from C9orf72 expansions, drive disease progression through diverse but converging mechanisms. TDP-43 proteinopathy, present in nearly all ALS cases, involves cytoplasmic mislocalization, misfolding, and aggregation, disrupting RNA processing, protein transport, and DNA repair. Similarly, SOD1 and FUS mutations promote toxic protein aggregation, impairing cellular homeostasis and contributing to neuronal dysfunction. C9orf72-derived DPRs exert toxicity by interfering with nucleocytoplasmic transport. The propagation of these pathogenic proteins between neurons and glia, often via prion-like mechanisms, underlies the characteristic spread of ALS pathology throughout the nervous system. Cellular protective responses, such as molecular chaperones and the ubiquitin-proteasome system, attempt to mitigate aggregation but are often overwhelmed in disease states. Mitochondrial dysfunction, oxidative stress, and disturbances in calcium homeostasis are also implicated, with evidence showing that SOD1 mutations can alter redox balance and mitochondrial function in both neurons and non-neuronal cells. Impaired DNA repair mechanisms, involving proteins such as TDP-43, FUS, NEK1, and VCP, have emerged as important contributors to ALS pathogenesis, linking protein aggregation to genomic instability. Recent therapeutic strategies focus on directly targeting misfolded proteins using small molecules, peptides, or antisense oligonucleotides to inhibit aggregation or enhance clearance, offering hope for disease modification. Understanding the interplay between protein aggregation, impaired RNA metabolism, and cellular stress responses is crucial for developing effective translational therapies for ALS.

  • Hippo-YAP/TAZ signaling in gastric cancer: molecular pathogenesis and emerging therapeutic horizons

    by Mandeep Kaur, Rachel Fabian Mungurere, Noah Mitinje, Gopal Krishna Sethi, Arora Sukhpreet Kaur, Aparna Mishra

    Gastric cancer remains a significant global health challenge, ranking as the 5th most common cancer worldwide with high mortality rates. Despite advances in diagnostic and therapeutic approaches, the prognosis for advanced gastric cancer remains poor due to its invasive nature and the lack of effective targeted treatments. The Hippo-YAP/TAZ signaling pathway, originally discovered in the fruit fly Drosophila melanogaster, has emerged as a critical regulator of cell proliferation, apoptosis, and organ size. Dysregulation of this pathway is increasingly implicated in gastric tumorigenesis. This pathway governs the activity of transcriptional co-activators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), through a core kinase cascade involving MST1/2 (Mammalian Ste20-like kinase 1/2), LATS1/2 (Large tumor suppressor kinase 1/2), and scaffold proteins such as SAV1 (Salvador homolog 1). Aberrations in the Hippo pathway have led to unchecked nuclear localization and transcriptional activity of YAP/TAZ, driving oncogenic gene expression that promotes cell survival, metastasis, and resistance to apoptosis. This review focuses on the molecular mechanisms underlying the dysregulation of the Hippo-YAP/TAZ signaling pathway in gastric cancer. It explores the crosstalk between Hippo-YAP/TAZ signalling and other oncogenic pathways, including Wnt/β-catenin and PI3K/Akt, as well as the influence of tumour microenvironmental factors such as hypoxia and extracellular matrix stiffness on pathway activation. Additionally, emerging therapeutic strategies targeting YAP/TAZ-TEAD interactions and upstream regulators are discussed, offering potential avenues for improving gastric cancer outcomes in diagnosis and treatment. Graphical Abstract


  • An evidence based comprehensive review on thiacloprid, a pesticide residue, induced toxicity: Unveiling hazard to human health

    by Tejinder Bir Singh, Mandeep Kaur, Devansh Tyagi, Israel Ahmad, Gurpreet Kaur, Shaikh Mohammad Afzal, Mohsin Jauhar


  • Exploring novel insights into the molecular mechanisms underlying Bisphenol A-induced toxicity: A persistent threat to human health

    by Israel Ahmad, Mandeep Kaur, Devansh Tyagi, Tejinder Bir Singh, Gurpreet Kaur, Shaikh Mohammad Afzal, Mohsin Jauhar


  • Molecular mechanisms of cognitive impairment associated with stroke

    by Mandeep Kaur, Saurabh Sharma

    Stroke is the second leading cause of death after coronary heart disease in developed countries and is the greatest cause of disability and cognitive impairment. Risk factors for cognitive impairment and dementia after stroke are multifactorial including older age, family history, hypertension, arterial fibrillation, diabetes, genetic variants, low educational status, vascular comorbidities, prior transient ischaemic attack or recurrent stroke, depressive illness duration of a stroke, location, volume, intensity, and degree of neuronal degeneration, location and size of infarction after stroke, time interval after stroke other cerebral dysfunctions. The pathophysiology of stroke associated cognitive impairment is complex and recent molecular, cellular, and animal models studies have revealed that multiple cellular changes have been implicated, including altered redox state, mitochondrial dysfunction, disruption of the blood-brain barrier, perivascular spacing, glymphatic system impairment, microglia activation and amyloid-β deposition in the parenchyma of the brain. These studies have also evidenced the involvement of various transcription factors, intracellular adhesion molecules, and endogenous growth factors in the pathogenesis of cognitive impairment associated with stroke and providing scope for developing therapeutic strategies for treatment. This review summarizes the latest research findings on molecular mechanisms involved in cognitive impairment associated with stroke.